WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place April 8-10, 2018, in Monte Carlo, Monaco.
Bellerophon Presentation Details
Date: Tuesday, April 10, 2018
Time: 10:15 AM Central European Summer Time/4:15 AM Eastern Time
Location: Monte Carlo, Monaco - Le Meridien Beach Plaza Hotel
The presentation will be webcast live and archived for 90 days on Bellerophon's Investor Relations website at investors.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767
LifeSci Advisors
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Bellerophon Therapeutics, Inc.